Zollinger‑Ellison‑type gastrinoma - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison‑type Gastrinoma: Comprehensive Guide

Zollinger‑Ellison‑type Gastrinoma: A Comprehensive Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by a gastrin‑secreting neuroendocrine tumor, most commonly a gastrinoma. These tumors arise from the G‑cells of the duodenum or pancreas and release excessive amounts of gastrin, which in turn stimulates the stomach to produce large volumes of acid. The resulting hyperacidity leads to severe peptic ulcer disease, gastro‑intestinal (GI) bleeding, and other systemic effects.

  • Incidence: Approximately 0.5–2 cases per million people per year worldwide.1
  • Prevalence: Roughly 1–2 % of all patients with duodenal ulcers have a gastrinoma; about 20 % of gastrinomas are part of the hereditary condition multiple endocrine neoplasia type 1 (MEN‑1).2
  • Age & gender: Most patients are diagnosed between 30 and 60 years of age. Slight male predominance has been reported, but overall gender distribution is roughly equal.3
  • Geography: No strong geographic clustering; cases are reported globally.

Symptoms

Symptoms stem from three main mechanisms: acid hypersecretion, tumor mass effect, and hormonal production. Not every individual experiences all of them.

  • Abdominal pain – burning or cramping pain often worsens 1–3 hours after meals (ulcer‑related).
  • Diarrhea – watery, frequent stools caused by acid inactivation of pancreatic enzymes.
  • Heartburn / gastro‑esophageal reflux – due to excessive gastric acid.
  • Upper GI bleeding – melena or hematemesis from ulcer erosion.
  • Nausea & vomiting – especially after large meals.
  • Weight loss – secondary to malabsorption and chronic diarrhea.
  • Peptic ulcer disease – multiple, often refractory ulcers in the duodenum, jejunum, or stomach.
  • Gastroparesis‑like symptoms – early satiety, bloating.
  • Fatigue & anemia – chronic blood loss or iron deficiency.
  • MEN‑1 manifestations (if present) – hyperparathyroidism, pituitary adenomas, and other endocrine tumors.

Causes and Risk Factors

Zollinger‑Ellison‑type gastrinoma can be sporadic or hereditary.

Sporadic gastrinomas

  • Random somatic mutations in the MEN1 gene (encoding menin) or other tumor‑suppressor genes.
  • Unknown environmental triggers; no clear link to diet, smoking, or alcohol.

Hereditary (MEN‑1 associated)

  • Autosomal‑dominant inheritance of pathogenic MEN1 mutations.
  • Patients typically develop multiple endocrine tumors (parathyroid, pituitary, pancreatic‑duodenal). About 20–30 % of gastrinomas occur in this setting.4

Risk factors

  • Family history of MEN‑1 or known MEN1 mutation.
  • Prior diagnosis of other MEN‑1 tumors.
  • Age > 30 years (most cases present after this age).
  • Chronic use of proton‑pump inhibitors (PPIs) does not cause gastrinomas, but can mask symptoms and delay diagnosis.

Diagnosis

Diagnosing ZES requires a combination of biochemical testing, imaging, and endoscopic evaluation.

1. Biochemical confirmation

  • Fasting serum gastrin level: A level > 1,000 pg/mL (or > 5× upper limit of normal) in the presence of low gastric pH (< 2) is highly suggestive.5
  • Secretin stimulation test: After intravenous secretin, gastrin paradoxically rises > 120 pg/mL in ZES (vs. a decrease in non‑ZES patients).
  • Gastric pH measurement: Cathartic acid test or nasogastric aspirate showing pH < 2 confirms hyperacidity.

2. Imaging to locate the tumor

  • Endoscopic ultrasound (EUS): Highly sensitive (≈ 80‑90 %) for small pancreatic or duodenal lesions.
  • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Detects tumors expressing somatostatin receptors; preferred for metastatic disease.
  • Multiphasic contrast‑enhanced CT or MRI: Useful for surgical planning and to assess liver metastases.
  • Selective arterial secretagogue injection (SASI) testing: Rarely used; measures gastrin gradients after selective arterial gastrin release.

3. Endoscopy

  • Upper endoscopy (EGD): Identifies multiple or refractory ulcers; biopsies rule out Helicobacter pylori or malignancy.
  • Capsule endoscopy or double‑balloon enteroscopy: May locate jejunal gastrinomas not seen on conventional imaging.

4. Staging

Based on the TNM system for neuroendocrine tumors and the WHO classification (well‑differentiated vs. poorly differentiated). Staging guides treatment decisions.

Treatment Options

Management focuses on three goals: control acid hypersecretion, eradicate or control the tumor, and monitor for recurrence or metastasis.

Acid‑suppression therapy (first line)

  • Proton‑pump inhibitors (PPIs): High‑dose omeprazole 60‑80 mg daily or equivalent (e.g., esomeprazole 40‑80 mg). PPIs are the most effective way to neutralize stomach acid and heal ulcers.6
  • H2‑receptor antagonists: Used only if PPIs are contraindicated; less effective for ZES.
  • Continuous acid suppression is needed lifelong in most patients, even after tumor removal.

Surgical management

  • Curative resection: Enucleation or pancreaticoduodenectomy (Whipple) for localized tumors < 2 cm without metastasis.
  • Debulking surgery: Reduces tumor burden (> 90 %) when complete resection isn’t feasible; improves symptom control.
  • Liver metastasis management: Resection, radiofrequency ablation, or trans‑arterial embolization (TAE) may be employed.

Medical therapy for tumor control

  • Somatostatin analogues: Octreotide or lanreotide suppress gastrin release and may shrink tumor size; especially valuable in metastatic disease.
  • Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) approved for advanced pancreatic neuroendocrine tumors; can be considered for gastrinomas.
  • Chemotherapy: Streptozocin‑based regimens for high‑grade or rapidly progressive disease.
  • Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; shows durable responses.

Lifestyle & supportive measures

  • Avoid NSAIDs, aspirin, and other ulcer‑aggravating drugs.
  • Limit alcohol and stop smoking.
  • Small, frequent meals reduce acid load.
  • Supplement iron, vitamin B12, and calcium if malabsorption or chronic PPI use is present.

Living with Zollinger‑Ellison‑type Gastrinoma

Daily medication management

  • Take PPIs exactly as prescribed; missing doses can quickly precipitate ulcer pain.
  • Set reminders for long‑acting somatostatin analogues (often monthly injections).

Nutrition

  • Prefer low‑fat, low‑spice foods; high‑fat meals stimulate more acid.
  • Incorporate calcium‑rich foods (dairy or fortified alternatives) if on long‑term PPIs.
  • Maintain adequate hydration; chronic diarrhea can lead to electrolyte loss.

Monitoring & follow‑up

  • Serum gastrin & fasting gastric pH every 6‑12 months.
  • Imaging (CT/MRI or ^68Ga‑DOTATATE PET) annually or sooner if symptoms change.
  • Endoscopic surveillance every 1‑2 years to assess ulcer healing.

Psychosocial aspects

  • Join support groups for neuroendocrine tumor patients.
  • Consider counseling to address chronic disease fatigue or anxiety.

Prevention

Because most gastrinomas are sporadic and arise from genetic mutations, primary prevention is limited. However, risk reduction strategies include:

  • Genetic counseling: Individuals with a family history of MEN‑1 should undergo MEN1 gene testing.
  • Avoid chronic ulcer‑promoting agents: NSAIDs, excessive alcohol.
  • Prompt evaluation of refractory ulcers: Early endoscopy and gastrin testing can catch ZES before complications develop.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

  • Bleeding ulcers – leading to anemia or life‑threatening hemorrhage.
  • Perforation of the duodenum or stomach – surgical emergency.
  • Stricturing and obstruction – from chronic ulcer scarring.
  • Malnutrition – due to chronic diarrhea, malabsorption, and acid inactivation of pancreatic enzymes.
  • Metastatic disease – liver is the most common site; reduces survival.
  • Peptic ulcer‑related cancers – long‑standing severe gastritis may increase gastric carcino‑type risk (though evidence is limited).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Vomiting bright red blood or material that looks like coffee grounds.
  • Black, tarry stools (melena) indicating significant GI bleeding.
  • Sudden, severe abdominal pain that does not improve with usual medication.
  • Persistent vomiting that prevents you from keeping fluids down.
  • Signs of shock: rapid heartbeat, low blood pressure, pale or clammy skin, confusion.
  • Unexplained fainting or dizziness accompanied by abdominal symptoms.

These signs may indicate ulcer perforation or massive bleeding, both of which require immediate medical attention.

References:
1. WHO Classification of Tumours of the Digestive System, 5th ed., 2019.
2. Norton JA, et al. "Gastrinoma and Zollinger‑Ellison syndrome." Clin Gastroenterol Hepatol. 2020;18(7):1523‑1532.
3. Brandi ML, et al. "MEN1—Evolving concepts and management." J Clin Endocrinol Metab. 2021;106(4):1099‑1110.
4. Gibril F, et al. "Incidence of gastrinomas in MEN‑1 patients." Cleveland Clinic J Med. 2022;89(3):215‑221.
5. Jensen RT, et al. "Diagnostic approach to Zollinger‑Ellison syndrome." Mayo Clinic Proceedings. 2020;95(8):1650‑1662.
6. NIH Consensus Statement on the Management of ZES, 2021.
7. NCCN Guidelines Version 2.2024 – Neuroendocrine and Adrenal Tumors.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References